Reuters/Ipsos poll: A quarter of Americans are hesitant about a coronavirus vaccine

Sunday, 24 May, 2020

Trials on monkeys also appeared to show the vaccine offered some protection against Covid-19.

Oxford University announced that its COVID-19 vaccine has entered its next phases of human trials, according to a statement on Friday, as British health authorities announced that 351 more people died from the disease across the United Kingdom over the past 24 hours. Immunity to the new coronavirus is uncertain and so the use of vaccines is unclear.

"Once the vaccine is ready it will go for animal trials to be followed by human clinical trials to assess its safety and efficacy which will take at least one year", a senior ICMR official told news agency PTI.

The pharmaceutical giant, in a statement on Thursday, said it can produce one billion doses of the vaccine - formerly ChAdOx1 nCoV-19 but now AZD1222 - having signed agreements and received aid to supply at least 400 million doses. Ministers have promised Britain will get first access to the vaccine.

There is a shortcoming with this vaccine, however, as many people have been exposed to Ad5, so those who already have antibodies to it might reject the vaccine.

"We have a lot of things happening on the vaccine front or the therapeutic front", Trump told reporters at the White House when asked about the AstraZenca announcement.

I can not say how long the procedure will drag on.

AstraZeneca has said that the production would take place in not just one country, but several.

Speaking about the recent Reuters survey, Dr. William Schaffner, an infectious disease and vaccine expert at Vanderbilt University Medical Centre in Nashville said: "It's a little lower than I thought it would be with all the attention to COVID-19".

Moderna on Monday outlined encouraging data from the trial, sending its shares soaring to record highs.

The first phase of the trial began last month with 1,000 healthy adults aged 55 and under as volunteers.

"Data from the trial is expected shortly which, if positive, would lead to late-stage trials in a number of countries".

Scientists at Israel's Tel Aviv University and biopharmaceutical company Neovii, for example, recently announced a project to develop a COVID-19 vaccine.

At the time of writing, there are more than 100 potential coronavirus vaccines in development.

Some experts have said the White House's emphasis on speed - its vaccine effort is called "Operation Warp Speed" - could leave people anxious that safety was being sacrificed for swiftness.

Other drugmakers including Pfizer Inc, J&J and Sanofi are in various stages of vaccine development.